Department of Neurology Klinikum Augsburg, Germany.
Acta Neurol Scand. 2011 Oct;124(4):290-2. doi: 10.1111/j.1600-0404.2010.01480.x. Epub 2011 Feb 9.
Natalizumab is neither licensed for the use in adolescents nor during pregnancy. There are no reports of accidental natalizumab exposure during pregnancy continued as long as to the third trimester of pregnancy.
We report the outcome of pregnancy in a 17-year-old adolescent patient with multiple sclerosis (MS) treated with natalizumab from the age of 16, who was diagnosed to be pregnant in the 31st gestational week (gw) of pregnancy. To our knowledge, this report describes the first patient receiving natalizumab to the third trimester of pregnancy.
Because of high relapse activity, natalizumab treatment was administered in an adolescent patient with MS. Pregnancy was diagnosed in the 31st gw after 17 natalizumab infusions, seven of them accidentally during pregnancy.
Pre- and postnatal development of the child was normal.
The case reported indicates that accidentally continued natalizumab treatment until few weeks before delivery may have no negative impact on the developing foetus.
那他珠单抗既未获准用于青少年患者，也未获准在妊娠期间使用。目前尚无妊娠期间意外持续使用那他珠单抗直至妊娠晚期（妊娠 3 个月）的报道。
我们报告了一例 17 岁青少年多发性硬化症（MS）患者的妊娠结局，该患者从 16 岁起开始接受那他珠单抗治疗，在妊娠第 31 孕周（gw）时被诊断为妊娠。据我们所知，这是首例报告在妊娠晚期（妊娠 3 个月）接受那他珠单抗治疗的患者。
由于高复发活动，该 MS 青少年患者接受了那他珠单抗治疗。在第 17 次那他珠单抗输注后第 31 个 gw 时诊断出妊娠，其中 7 次是在妊娠期间意外接受的。
患儿的产前和产后发育正常。
该病例报告表明，妊娠前几周意外持续使用那他珠单抗治疗可能对发育中的胎儿没有负面影响。
